Doximity (NYSE:DOCS) CAO Siddharth Sitaram Sells 2,613 Shares of Stock

Doximity, Inc. (NYSE:DOCS) CAO Siddharth Sitaram sold 2,613 shares of the company’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $30.68, for a total value of $80,166.84. Following the transaction, the chief accounting officer directly owned 101,432 shares in the company, valued at $3,111,933.76. This represents a 2.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Siddharth Sitaram also recently made the following trade(s):

• On Tuesday, September 15th, Siddharth Sitaram sold 2,077 shares of Doximity stock. The shares were sold at an average price of $26.02, for a total value of $54,043.54.
• On Thursday, August 13th, Siddharth Sitaram sold 1,770 shares of Doximity stock. The shares were sold at an average price of $24.94, for a total value of $44,143.80.

Doximity Price Performance

Shares of NYSE DOCS traded down $0.69 during trading on Friday, hitting $30.81. 3,582,714 shares of the company were exchanged, compared to its average volume of 3,332,407. The company has a market cap of $5.49 billion, a price-to-earnings ratio of 36.25, a PEG ratio of 24.64 and a beta of 1.22. Doximity, Inc. has a 1 year low of $17.15 and a 1 year high of $71.37. The firm’s fifty day moving average price is $26.75 and its 200 day moving average price is $23.63.

Doximity (NYSE:DOCS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The business had revenue of $156.62 million during the quarter. During the same quarter in the prior year, the business earned $0.36 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. On average, research analysts forecast that Doximity, Inc. will post 0.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on DOCS shares. Wolfe Research raised shares of Doximity to an “outperform” rating in a report on Thursday, August 13th. Barclays boosted their price target on Doximity from $20.00 to $27.00 and gave the stock an “equal weight” rating in a research note on Friday, August 21st. Zacks Research raised Doximity from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Stifel Nicolaus set a $27.00 price objective on Doximity in a report on Tuesday, September 8th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $38.00 target price on shares of Doximity in a research report on Friday. Eight equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $30.73.

Key Headlines Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity extended its 13-year alliance with U.S. News, supporting physician searches, appointment booking and hospital rankings. The partnership could reinforce user engagement and patient-access offerings. Doximity Deepens U.S. News Alliance to Improve Patient Access to Care
• Neutral Sentiment: Doximity will release fiscal 2027 second-quarter results on November 5, giving investors the next major opportunity to assess growth, advertising trends and management’s outlook. Doximity to Release Fiscal 2027 Second Quarter Results on November 5, 2026
• Negative Sentiment: Several law firms publicized a securities-fraud class action against Doximity and certain individuals, including co-founder and former Chief Strategy Officer Nate Gross. The allegations reportedly concern statements that Doximity could gain market share while older advertising formats were losing ground to programmatic and social-media competitors; the claims have not been established in court.
• Negative Sentiment: Investors who purchased DOCS shares between August 8, 2024 and May 13, 2026 are being reminded that November 16, 2026 is the deadline to seek appointment as lead plaintiff. Repeated announcements from Robbins Geller, SBS Law, Kaplan Fox, Rosen, Pomerantz, Bronstein Gewirtz Grossman and other firms increase the visibility of the legal overhang and could weigh on sentiment. DOCS Investor Alert

Institutional Trading of Doximity

Institutional investors and hedge funds have recently modified their holdings of the business. Carmignac Gestion increased its stake in shares of Doximity by 127.8% during the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after purchasing an additional 2,418,971 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Doximity by 29.4% in the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock valued at $71,292,000 after buying an additional 694,300 shares in the last quarter. Wellington Management Group LLP lifted its stake in Doximity by 24.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock valued at $65,022,000 after buying an additional 621,464 shares in the last quarter. SG Americas Securities LLC lifted its stake in Doximity by 3,403.2% in the 1st quarter. SG Americas Securities LLC now owns 1,408,597 shares of the company’s stock valued at $32,820,000 after buying an additional 1,368,388 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in Doximity during the 3rd quarter valued at $28,858,000. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity Company Profile

Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.

The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.

Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.